diabetestalk.net

Diabetes Breakthrough: Insulin-producing Cells Formed Using Malaria Drugs

Diabetes breakthrough: Insulin-producing cells formed using malaria drugs

Diabetes breakthrough: Insulin-producing cells formed using malaria drugs

Diabetes currently affects 29 million Americans. For decades, researchers have been trying to replace the insulin cells of the pancreas that are destroyed by the disease. Groundbreaking research may have found a way to genetically transform alpha cells into insulin-producing beta cells.
Diabetes ranks as the seventh leading cause of death in the United States, according to the Centers for Disease Control and Prevention (CDC).
The CDC report that 29 million Americans currently live with the disease, and another 86 million have prediabetes.
Type 1 diabetes is characterized by the inability of the pancreas to produce insulin. More specifically, the body's own immune system stops recognizing the beta cells normally responsible for producing insulin. Instead, it attacks and destroys them.
Without insulin - which normally "tells" the body to start reducing the levels of glucose - the blood sugar cannot enter the cells, where it is normally transformed into energy. As a result, glucose gets stuck in the bloodstream, leading to diabetes.
For decades, scientists have been trying to find a way to replace these beta cells - sometimes referred to as islet cells because they are located in an endocrine area of the pancreas known as the islets of Langerhans.
Researchers have attempted to replace destroyed beta cells with new ones using stem cells and adult cells. Although the results have looked encouraging, they have yet to succeed.
Now, researchers from the CeMM Research Center for Molecular Medicine in Austria seem to have found the missing link, giving hope of a cure for type 1 diabe Continue reading

Rate this article
Total 1 ratings
FDA approves Medtronic's 'artificial pancreas' for diabetes

FDA approves Medtronic's 'artificial pancreas' for diabetes

Medtronic Plc won U.S. approval on Wednesday for an "artificial pancreas" that is the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes, freeing them from continually monitoring insulin levels throughout each day.
The U.S. Food and Drug Administration, in its approval of the device, the MiniMed 670G, hailed it as a breakthrough.
The device offers type 1 diabetics "greater freedom to live their lives without having to consistently and manually monitor baseline glucose levels and administer insulin," Dr. Jeffrey Shuren, director of the FDA's medical device division, said in a statement.
Analysts said the FDA approved the device six months sooner than expected. However, it will not be available until the spring of 2017.
The MiniMed 670G is the first device that allows a glucose sensor to communicate with an insulin pump and automatically regulate the insulin flow. The device is approved for those aged 14 and older.
The device measures glucose levels every five minutes and automatically administers insulin as needed. Patients will still need to instruct the device to deliver extra insulin for meals and notify the device when they exercise - which lowers glucose levels.
About 1.25 million American children and adults have type 1 diabetes, a condition in which the pancreas produces little or no insulin - a hormone needed to obtain energy from food.
Patients take insulin injections at various times of the day. But blood sugar can drop to dangerously low levels if too much insulin circulates in the bloodstream, requiring patients to fr Continue reading

The musculoskeletal effects of diabetes mellitus

The musculoskeletal effects of diabetes mellitus

Go to:
Abstract
Diabetes mellitus (DM) is a multi-system disease characterized by persistent hyperglycemia that has both acute and chronic biochemical and anatomical sequelae, with Type-2 DM representing the most common form of the disease. Neuromusculoskeletal sequelae of DM are common and the practicing chiropractor should be alert to these conditions, as some are manageable in a chiropractic office, while others are life and/or limb threatening. This paper reviews the effects of DM on the musculoskeletal system so as assist the chiropractor in making appropriate clinical decisions regarding therapy, understanding contraindications to therapy, referring patients to medical physicians when appropriate and understanding the impact that DM may have on the prognosis for their patients suffering from the myriad musculoskeletal conditions associated with this disease.
Keywords: diabetes, musculoskeletal, chiropractic
Go to:
Introduction
Diabetes mellitus (DM) is a multi-system disease characterized by persistent hyperglycemia that has both acute and chronic biochemical and anatomical sequelae. It is thought to affect almost 17 million Americans, only 11 million of whom have been diagnosed according to the American Diabetes Association.
In type 1 diabetes, a lack of insulin results in poor carbohydrate, fat, and protein metabolism. Insulin is functionally absent, typically due to immune-mediated destruction of the beta cells of the pancreas, though other etiologies of beta cell destruction have also been implicated, including drugs, chemicals, viruses, mitochondrial gene defects Continue reading

New Type of Insulin-Producing Cell Discovered

New Type of Insulin-Producing Cell Discovered

Possible new route to regenerating function lost in diabetes
In people with type I diabetes, insulin-producing beta cells in the pancreas die and are not replaced. Without these cells, the body loses the ability to control blood glucose. Researchers at the University of California, Davis have now discovered a possible new route to regenerating beta cells, giving insight into the basic mechanisms behind healthy metabolism and diabetes. Eventually, such research could lead to better treatment or cures for diabetes.
“We’ve seen phenomenal advances in the management of diabetes, but we cannot cure it,” said Mark Huising, assistant professor of neurobiology, physiology and behavior in the UC Davis College of Biological Sciences. “If you want to cure the disease, you have to understand how it works in the normal situation.”
Huising is senior author on a paper on the work published April 4 in the journal Cell Metabolism.
Working with both laboratory mice and human tissue, Huising is studying how the cells in the islets of Langerhans in the pancreas work together to regulate blood glucose. In both mice and people, the islets contain beta cells, which detect glucose and secrete insulin, and other cell types including alpha cells that produce glucagon, a hormone that raises blood sugar. The opposite effects of insulin and glucagon enable the body to regulate blood sugars and store nutrients.
Type I diabetes is a disease with two parts. Firstly, the beta cells are killed by the body’s own immune system, and then they fail to regenerate (or those that do are killed). An eff Continue reading

Diabetes breakthrough increases insulin producing cells

Diabetes breakthrough increases insulin producing cells

A potential cure for Type 1 diabetes looms on the horizon in San Antonio, and the novel approach would also allow Type 2 diabetics to stop insulin shots.
The discovery, made at UT Health San Antonio, increases the types of pancreatic cells that secrete insulin.
UT Health San Antonio researchers have a goal to reach human clinical trials in three years, but to do so they must first test the strategy in large-animal studies, which will cost an estimated $5 million.
Those studies will precede application to the U.S. Food and Drug Administration for Investigational New Drug (IND) approval, Bruno Doiron, Ph.D., a co-inventor, said.
The scientists received a U.S. patent in January, and UT Health San Antonio is spinning out a company to begin commercialization.
The strategy has cured diabetes in mice.
“It worked perfectly,” Dr. Doiron, assistant professor of medicine at UT Health, said. “We cured mice for one year without any side effects. But it’s a mouse model, so caution is needed. We want to bring this to large animals that are closer to humans in physiology of the endocrine system.”
Ralph DeFronzo, M.D., professor of medicine and chief of the Division of Diabetes at UT Health, is co-inventor on the patent. He described the therapy:
“The pancreas has many other cell types besides beta cells, and our approach is to alter these cells so that they start to secrete insulin, but only in response to glucose [sugar],” he said. “This is basically just like beta cells.”
Insulin, which lowers blood sugar, is only made by beta cells. In Type 1 diabetes, beta cells are d Continue reading

No more pages to load

Popular Articles

Related Articles